Monday, December 23

CG Oncology and ArriVent Raise $555M in IPOs

CG Oncology and ArriVent Raise a Combined $555M in IPOs

CG Oncology

  • CG Oncology plans to use $183.8 million of the net proceeds from its IPO to fund research and development for cretostimogene, as well as manufacturing activities.
  • The remaining funds will be allocated for working capital, general corporate purposes, and pre-commercial activities.

ArriVent

  • ArriVent intends to set aside $50 million to $60 million of its IPO proceeds to support NDA activities for furmonertinib, specifically for its use as a first-line therapy for patients with EGFRm NSCLC involving exon 20 insertion mutations.

CG Oncology and ArriVent have successfully raised a combined total of $555 million through their IPOs. CG Oncology plans to allocate a significant portion of its proceeds towards the research and development of cretostimogene, while ArriVent intends to use a large share of its funds to support NDA activities for furmonertinib. These successful IPOs demonstrate investor confidence in the potential of these biotechnology companies and their innovative therapies.


Click here for the original article.